Logo image of ALXN

Alexion Pharm Inc (ALXN) Stock Fundamental Analysis

NASDAQ:ALXN - Nasdaq -

182.5  +3.05 (+1.7%)

After market: 183 +0.5 (+0.27%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ALXN. ALXN was compared to 571 industry peers in the Biotechnology industry. ALXN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALXN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALXN had positive earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA 3.66%
ROE 5.48%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 9.15%
PM (TTM) 10.89%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

There is no outstanding debt for ALXN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 5.06 indicates that ALXN is not in any danger for bankruptcy at the moment.
ALXN has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 5.06
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 4.52 indicates that ALXN has no problem at all paying its short term obligations.
ALXN has a Quick Ratio of 3.96. This indicates that ALXN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.52
Quick Ratio 3.96

More info and screens

5

3. Growth

3.1 Past

ALXN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.94%, which is quite good.
ALXN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.12% yearly.
The Revenue has grown by 18.24% in the past year. This is quite good.
ALXN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.44% yearly.
EPS 1Y (TTM)12.94%
EPS 3Y28.83%
EPS 5Y20.12%
EPS Q2Q%9.32%
Revenue 1Y (TTM)18.24%
Revenue growth 3Y19.57%
Revenue growth 5Y18.44%
Sales Q2Q%13.27%

3.2 Future

ALXN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.32% yearly.
Based on estimates for the next years, ALXN will show a small growth in Revenue. The Revenue will grow by 7.94% on average per year.
EPS Next Y9.86%
EPS Next 2Y8.02%
EPS Next 3Y8.65%
EPS Next 5Y6.32%
Revenue Next Year12.08%
Revenue Next 2Y9.81%
Revenue Next 3Y8.89%
Revenue Next 5Y7.94%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALXN Yearly Revenue VS EstimatesALXN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
ALXN Yearly EPS VS EstimatesALXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 14.22, ALXN is valued correctly.
When comparing the Price/Earnings ratio of ALXN to the average of the S&P500 Index (29.62), we can say ALXN is valued rather cheaply.
With a Price/Forward Earnings ratio of 12.48, ALXN is valued correctly.
ALXN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.70.
Industry RankSector Rank
PE 14.22
Fwd PE 12.48
ALXN Price Earnings VS Forward Price EarningsALXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.39
ALXN Per share dataALXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.44
PEG (5Y)0.71
EPS Next 2Y8.02%
EPS Next 3Y8.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALXN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Alexion Pharm Inc

NASDAQ:ALXN (7/20/2021, 9:56:13 PM)

After market: 183 +0.5 (+0.27%)

182.5

+3.05 (+1.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)02-22 2022-02-22/bmo
Inst Owners0%
Inst Owner Change11283.6%
Ins Owners0.8%
Ins Owner Change0%
Market Cap40.34B
Analysts66.2
Price Target180.9 (-0.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 14.22
Fwd PE 12.48
P/S 6.44
P/FCF N/A
P/OCF N/A
P/B 3.24
P/tB N/A
EV/EBITDA 13.39
EPS(TTM)12.83
EY7.03%
EPS(NY)14.62
Fwd EY8.01%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS28.33
BVpS56.24
TBVpSN/A
PEG (NY)1.44
PEG (5Y)0.71
Profitability
Industry RankSector Rank
ROA 3.66%
ROE 5.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 9.15%
PM (TTM) 10.89%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.52
Quick Ratio 3.96
Altman-Z 5.06
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.94%
EPS 3Y28.83%
EPS 5Y20.12%
EPS Q2Q%9.32%
EPS Next Y9.86%
EPS Next 2Y8.02%
EPS Next 3Y8.65%
EPS Next 5Y6.32%
Revenue 1Y (TTM)18.24%
Revenue growth 3Y19.57%
Revenue growth 5Y18.44%
Sales Q2Q%13.27%
Revenue Next Year12.08%
Revenue Next 2Y9.81%
Revenue Next 3Y8.89%
Revenue Next 5Y7.94%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A